Literature DB >> 23192843

Cell cycle-dependent expression of p42.3 promotes mitotic progression in malignant transformed cells.

Linlin Mao1, Wei Sun, Wenmei Li, Jiantao Cui, Jingyu Zhang, Rui Xing, Youyong Lu.   

Abstract

In an earlier study, we cloned the p42.3 gene and showed that its expression was specific to tumors in a number of tumor cell lines and primary tumor tissues. However, the biological role and function of this gene remains largely unknown. In this study, p42.3 expression was found to be cell cycle-dependent at both the mRNA and protein levels in several human tumor cell lines. Typically, abundant expression was detected at G1 and M phases compared with S and G2 phases. Expression peaked at early G1 phase then decreased drastically at late G1, S, and G2. Furthermore, transfection of the p42.3 gene into NIH3T3 cells promoted malignant transformation, accompanied by accelerated mitotic progression and altered chromosome segregation. It was also observed that Cyclin B1 was upregulated and Cdc2-Tyr15 was downregulated following p42.3 overexpression in NIH3T3 cells. Combined, these results indicate that p42.3 as a cell cycle-regulated gene contributes to promoting cell cycle progression through disruption of mitotic regulation, and may play important roles in malignant transformation.
© 2012 Wiley Periodicals, Inc.

Entities:  

Keywords:  cell cycle; cell transformation; early G1; mitotic progression; p42.3

Mesh:

Substances:

Year:  2012        PMID: 23192843     DOI: 10.1002/mc.21982

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  9 in total

1.  p42.3 promotes cell proliferation and invasion in human Renal-Cell Carcinoma.

Authors:  Pei-Hua Li; Wen-Jia Cao; Lin-Lin Mao; Hui Huang; Jun-Nian Zheng; Dong-Sheng Pei
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells.

Authors:  Hui Liu; Min Zhu; Zhongwu Li; Yan Wang; Rui Xing; Youyong Lu; Weicheng Xue
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-16       Impact factor: 4.553

3.  A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model.

Authors:  Hu Liu; Shuang Geng; Congcong Feng; Xiaoping Xie; Bing Wu; Xuan Chen; Qiang Zou; Shuang Wang; Jiantao Cui; Rui Xing; Wenmei Li; Youyong Lu; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

4.  Expression of p42.3 in non-small cell lung cancer.

Authors:  Xinmu Zhang; Xin Nie; Junyu Long; Jiangyong Yu; Ping Zhang; Yan Liu; Xiaonan Wu; Yi Bai; Jinzhu Mao; Xiaochuan Liu; Yue Yuan; Haitao Zhao; Lin Li
Journal:  Ann Transl Med       Date:  2020-07

Review 5.  The Function and Regulation of SAPCD2 in Physiological and Oncogenic Processes.

Authors:  Amy L Baker; Liqin Du
Journal:  J Cancer       Date:  2022-04-18       Impact factor: 4.478

6.  Overexpression of p42.3 promotes cell proliferation, migration, and invasion in human gastric cancer cells.

Authors:  Wen-Jia Cao; Wen-Qi Du; Lin-Lin Mao; Jun-Nian Zheng; Dong-Sheng Pei
Journal:  Tumour Biol       Date:  2016-07-23

7.  Overexpression of p42.3 promotes cell growth and tumorigenicity in hepatocellular carcinoma.

Authors:  Wei Sun; Wei-Wei Dong; Lin-Lin Mao; Wen-Mei Li; Jian-Tao Cui; Rui Xing; You-Yong Lu
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

8.  Overexpression of SAPCD2 correlates with proliferation and invasion of colorectal carcinoma cells.

Authors:  Yage Luo; Lili Wang; Wenwen Ran; Guangqi Li; Yujing Xiao; Xiaonan Wang; Han Zhao; Xiaoming Xing
Journal:  Cancer Cell Int       Date:  2020-02-06       Impact factor: 5.722

9.  Efficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: A Randomized Active-Controlled Clinical Trial.

Authors:  Ruilin Wang; Yanling Wang; Zheng Lu; Jing Jing; Zhongxia Wang; Tingting He; Miao Tian; Zongyang Yuan; Yanfei Cui; Wenya Rong; Xiao Ma; Yanling Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-07       Impact factor: 2.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.